2022
Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma
Eugster PJ, Maurer J, Vocat C, Abid K, Matter M, Wuerzner G, Trepp R, Fischli S, Henzen C, Kolb W, Bilz S, Sigrist S, Beuschlein F, Nölting S, Reul A, Schütze I, Hubers SA, Brown NJ, Grouzmann E. Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. Clinica Chimica Acta 2022, 534: 146-155. PMID: 35905838, DOI: 10.1016/j.cca.2022.07.018.Peer-Reviewed Original ResearchConceptsUpper reference limitPlasma free metanephrinesNeuropeptide YSevere kidney impairmentFree metanephrinesNPY3-36Kidney impairmentSympathetic nervesCatecholamine reuptakeVasoconstrictor peptideNPY2-36NPY1-36Early diagnosisHealthy volunteersPPGL patientsAdrenal medullaTumor localizationPatientsNPYReference limitsDiagnostic sensitivityPPGLsGold standardReference intervalsPheochromocytoma
2019
Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS
Vocat C, Dunand M, Hubers SA, Bourdillon N, Millet G, Brown NJ, Wuerzner G, Grouzmann E, Eugster PJ. Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry 2019, 92: 859-866. PMID: 31790196, PMCID: PMC8541045, DOI: 10.1021/acs.analchem.9b03505.Peer-Reviewed Original ResearchConceptsNeuropeptide YNPY3-36Hypertensive patientsHealthy volunteersConcentrations of NPYEndogenous neuropeptide YHuman plasmaNPY2-36Pathological processesReference intervalsEndogenous peptidesChromatography-tandem mass spectrometryPatientsAcid peptideMS/MSVolunteersMetabolitesInter-assay precisionPeptidesPrototype peptideTandem mass spectrometryDistinct effectsOrthostasisCatecholaminesSubpicomolar concentrations
2018
DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition
Hubers SA, Wilson JR, Yu C, Nian H, Grouzmann E, Eugster P, Shibao CA, Billings FT, Jafarian Kerman S, Brown NJ. DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition. Hypertension 2018, 72: 712-719. PMID: 29987109, PMCID: PMC6202157, DOI: 10.1161/hypertensionaha.118.11498.Peer-Reviewed Original ResearchConceptsNPY infusionPlacebo-controlled crossover studyAngiotensin-converting enzyme inhibitorAldosterone system inhibitionDose-dependent vasoconstrictionIntra-arterial enalaprilatAngiotensin receptor blockersForearm blood flowHigh-risk patientsOrder of treatmentReceptor blockersVasoconstrictor effectVasoconstrictor responsesCardiovascular effectsRenin-AngiotensinBrachial arteryHeart failureNorepinephrine releaseCrossover studyEndogenous NPYY1 receptorCrossover treatmentSystem inhibitionY2 receptorsDPP4 inhibition